Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Adverse events: neurotoxicity (grade 3/4) ( · adjuvant therapy for early breast cancer

Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).

1 finding from 1 review

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
RR 0.78 [0.25, 2.46]
3 studies · 162 participants
Low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Adverse events: neurotoxicity (grade 3/4) ( · neoadjuvant therapy for early breast cancer

Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).

1 finding from 1 review

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
RR 0.95 [0.55, 1.65]
2 studies · 1108 participants
Low